Picking out the really good things from this article since no one is going to get rich off of IMGN stock anytime soon . . .
Roche is assessing Kadcyla in a number of additional indications:
including for first-line treatment of HER2-positive metastatic BC (MARIANNE trial),
for uses in early stage HER2-positive BC (including the KATHERINE trial),
and for the treatment of advanced HER2-positive
stomach cancer (GATSBY trial).
The progression-free survival (PFS) endpoint of TH3RESA has been met, and Roche intends to submit these data for presentation at the ESMO annual meeting Sept. 27-Oct. 1, 2013.
Roche expects results from MARIANNE in late 2014 and to apply for
first-line treatment of HER2-positive metastatic BC and for treatment of advanced HER2-positive
gastric cancer in 2015.
Threaded Mode